

# Protective effect of BCG vaccination in a nursery outbreak in 2009: time to reconsider the vaccination threshold?

J Eriksen,<sup>1,2</sup> J Y Chow,<sup>3</sup> V Mellis,<sup>3</sup> B Whipp,<sup>3</sup> S Walters,<sup>4</sup> E Abrahamson,<sup>5</sup> I Abubakar<sup>6,7</sup>

## See Editorial, p 1036

<sup>1</sup>European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden and HPA Centre for Infections, London, UK

<sup>2</sup>HPA Centre for Infections, London, UK

<sup>3</sup>North West London Health Protection Unit, HPA, UK

<sup>4</sup>St Mary's Hospital, London, UK

<sup>5</sup>Chelsea and Westminster Hospital, London, UK

<sup>6</sup>TB Section, HPA Centre for Infections, London, UK

<sup>7</sup>School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK

## Correspondence to

Jaran Eriksen, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London N1 6JB, UK; [jaran.eriksen@ki.se](mailto:jaran.eriksen@ki.se)

Received 6 April 2010

Accepted 16 September 2010

Published Online First

28 October 2010

## ABSTRACT

**Background** In July 2008 a case of smear-positive pulmonary tuberculosis (TB) in a white UK-born nursery teacher was notified in London. The case had been symptomatic for 9 months while working in the nursery. The outbreak is described and the protective effect of BCG vaccination against latent *Mycobacterium tuberculosis* infection as measured by an interferon gamma release assay (IGRA) is assessed.

**Methods** Screening by chest X-ray and IGRA of nursery children, staff and their contacts was conducted using a 'stone-in-the pond' approach. Information was collected on various factors including BCG vaccination status, and data were analysed using multivariable logistic regression.

**Results** Overall, 168 children, 31 staff members and 57 other adults associated with the nursery were screened for TB. There were 12 cases of active TB and 43 cases of latent TB (72% children). 37.5% (95% CI 18% to 56%) and 40% (95% CI 30% to 50%) had a positive IGRA among teachers and children, respectively. 42% of children and 60% of adults were BCG vaccinated. In the adjusted analysis, BCG vaccination showed a significant protective effect against *M tuberculosis* infection in children (OR 0.25, 95% CI 0.09 to 0.69) and being taught by the index case was associated with acquiring TB infection (OR 18.91, 95% CI 4.43 to 80.79). A vaccine effectiveness of 66% was calculated, implying that 21 of the 32 infections could have been avoided if all children had been vaccinated with BCG.

**Conclusions** This outbreak shows extensive transmission of TB among very young children. BCG seems to have a protective effect against TB infection as assessed by positive IGRA in this cohort.

## BACKGROUND

The incidence of tuberculosis (TB) in the UK, and in particular in London, has increased over the last two decades.<sup>1</sup> This has been accompanied by a change in the epidemiology of TB, with the disease now largely concentrated in certain population groups. The incidence of TB among children aged <5 years in the UK remains low.<sup>2</sup> In 2005, despite the overall increase in TB cases, the Department of Health changed the UK policy on Bacillus Calmette-Guerin (BCG) vaccination from the general vaccination of all schoolchildren to a selective policy targeting infants with a high risk of acquiring TB and certain other risk groups.<sup>3</sup> This decision was made in part because the UK met the criteria set by the International Union against

Tuberculosis and Lung Disease<sup>4</sup> for a selective BCG vaccination policy.

Several risk factors have been associated with an increased risk of acquiring tuberculous infection. Among these are immunosuppression, old age, smoking and contact with someone who has infectious TB including through travelling to or living in areas that are highly endemic for TB (>40 cases/100 000 population/year).<sup>5</sup> The latter is reflected in the current UK policy on BCG vaccination<sup>6</sup> which recommends immunisation of all infants (aged 0–12 months) living in areas of the UK where the annual incidence of TB is >40/100 000, all infants (with catch-up to 16 years of age) with a parent or grandparent born in a high-incidence country (annual incidence of TB >40/100 000), new entrants <16 years born in or who have lived for at least 3 months in a high-incidence country, individuals at occupational risk and travellers aged <35 years going to high-incidence areas for >3 months.<sup>6</sup>

Meta-analyses indicate that BCG vaccination is effective in reducing the risk of severe manifestations of TB and that it reduces the risk of acquiring TB in newborns by, on average, 50%.<sup>7–8</sup> It has been difficult, however, to determine the effect of BCG vaccination on the risk of infection with *Mycobacterium tuberculosis* because the methods traditionally used for testing (eg, tuberculin skin test) do not distinguish between the effect of BCG vaccination and that of *M tuberculosis* infection.<sup>9</sup> The interferon  $\gamma$  release assay (IGRA) is a blood test which measures interferon  $\gamma$  release of T lymphocytes stimulated by *M tuberculosis* antigens not present in *M bovis* BCG. It can therefore detect an immune response to *M tuberculosis* infection without also including the positive results induced by a prior BCG vaccination. IGRA performed in contacts of patients with infectious pulmonary TB for identification of individuals who have latent *M tuberculosis* infection is not confounded by prior BCG vaccination as is the tuberculin skin test,<sup>10</sup> making it possible to study the protective effect of BCG against latent tuberculous infection as suggested by recent studies.<sup>9–11–12</sup>

In July 2008 the North West London Health Protection Unit (HPU) was contacted about a case of smear-positive pulmonary TB in a UK-born teacher who worked in a nursery in London. The case had been undiagnosed and symptomatic while working in the nursery for 9 months. Public health investigations led to the identification and management of an outbreak in the nursery. This

paper describes the outbreak and assesses whether BCG vaccination has a protective effect against *M tuberculosis* infection.

## METHODS

### The outbreak

The index case was a UK-born adult of British white ethnicity. The case was investigated by her GP because of a prolonged history of cough, tiredness and weight loss. The case had no history of travel to high-incidence areas during the last 2 years and had been vaccinated with BCG as a teenager. The case had been suffering from chronic cough and weight loss for 9 months and was initially diagnosed with 'bronchitis' before being diagnosed with TB (three sputum samples, all with mucopurulent appearance, acid-fast bacilli seen in all three samples, cultured as fully sensitive *M tuberculosis*, IGRA positive and x-ray changes compatible with pulmonary TB). The case was then immediately started on a 6-month course of antituberculous treatment. Household and close contact tracing was performed and a risk assessment was conducted at her workplace.

The index case was a nursery teacher. Active case finding was conducted where all children and staff who had been exposed in the nursery while the index case was symptomatic were contacted for screening of TB. The screening was conducted according to the 'stone-in-the-pond' principle<sup>13</sup> whereby all close contacts of each new active case of TB were screened.

### The setting

The workplace of the index case was a private nursery located in one of the most affluent parts of London. More than 90% of the children lived in either Kensington and Chelsea or Westminster boroughs of London, areas with a relatively low incidence of TB (in 2007, 29.1 and 29.9/100 000, respectively) but originated from diverse countries, mostly with a low incidence of TB.

The children who regularly attended the nursery were 2–5 years old, but there was also a weekly 1 h carer and toddler group where each toddler came with an adult carer. The nursery also ran a 'summer camp', a day nursery for children who were in London over the summer. The term for all the children had ended just before the index case was diagnosed with TB and the screening of contacts started 6 weeks after the last possible contact with the index case.

All individuals seen at a public hospital in this outbreak were seen at either St Mary's or Chelsea and Westminster hospitals in London. All IGRA tests were performed at St Mary's hospital using the QuantiFERON-TB Gold In-Tube assay (Cellestis, Darmstadt, Germany). QuantiFERON uses the region of difference-1 antigen's early secretory antigen targets 6 (ESAT-6) and TB 7.7, and culture filtrate protein 10 (CFP 10) to stimulate T effector cells specific for *M tuberculosis* to produce interferon  $\gamma$ . Those with a positive IGRA test from any screening round were recalled for a chest x-ray examination and clinical review. All previously unvaccinated children with a negative IGRA test were offered BCG vaccination.

### Data collection

All children were assessed by the local paediatric and TB teams using a questionnaire and IGRA tests. For logistic purposes, all contacts were also screened by chest x-ray and baseline liver function tests were performed at the same time. At the time of screening, information on age, sex, BCG vaccination status, country of origin and contact with the nursery and the index case was collected. BCG vaccination status was assessed by vaccination card and/or BCG scar.

## Definitions

Close contact: a person with a cumulative total exposure to a smear-positive case of TB exceeding 8 h within a restricted area equivalent to domestic rooms/class rooms.<sup>5</sup>

Latent *M tuberculosis* infection: in this outbreak, refers to an asymptomatic person with a positive IGRA test and a normal chest x-ray.

Active TB disease: x-ray changes compatible with TB in a person with a positive IGRA test and symptoms of TB where a decision to treat with a full course of antituberculous drugs has been taken, with or without the isolation of *M tuberculosis*.

## Data analysis

Data were entered in Microsoft Excel and later imported to Stata 10.1 for analysis. We calculated attack rates and performed logistic regression for associations between latent TB infection and BCG vaccination, age, sex and having been taught by the index case. Adjusted ORs were used to get an approximation of the RR using the following formula:  $RR = OR / ((1 - P_o) + (P_o \times OR))$  where  $P_o$  = incidence of outcome of interest (ie, infection rate in the group not BCG vaccinated) as described by Zhang and Yu.<sup>14</sup> This formula is used to correct the adjusted OR obtained from logistic regression and to derive an estimate of an association or treatment effect that better represents the true RR. This RR approximation was used to calculate RR reductions/vaccine effectiveness (VE) using the formula  $VE = 1 - RR$ .

## RESULTS

Using the 'stone-in-the-pond' approach,<sup>13</sup> 168 children, 31 staff members and 57 other adults associated with the nursery were screened for TB (figure 1). Among those in whom the BCG vaccination status was known (figure 2), 42% (53/126) of the children and 60% (32/53) of the adults were BCG vaccinated (table 1).

### Nursery contacts

Among the 256 nursery contacts screened, we found 12 active TB cases and 42 individuals with latent infection; 72% of these were children (table 1). The attack rate for infection, measured as IGRA positivity, was 9/24=37.5% (95% CI 18% to 56%) and 35/86 = 40.7% (95% CI 30.3 to 51.1) among teachers and children, respectively. For active disease, the rates were 2/24=8.3% (95% CI 2% to 14%) and 7/86=8.1% (95% CI -3% to 19%) for adults and children, respectively. Of 79 individuals with known place of birth, only 7 were from a country with a high incidence of TB. The median age of children was 2.6 years (IQR=1.5). Among the children, a significantly lower proportion of IGRA positivity was seen in BCG vaccinated individuals than in non-vaccinated individuals (13% vs 36%,  $p=0.008$ , 126 observations; table 2).

### Univariable analysis


Among the 168 children, no significant association was found between tuberculous infection and age or sex (table 2). Information on country of birth was available for 66 children, 2 of whom came from a high-incidence country. Being taught by the index case was associated with a positive IGRA test (OR 11.61, 95% CI 3.87 to 34.83) and BCG vaccination showed a protective effect against infection (OR 0.28, 95% CI 0.11 to 0.70, table 2).

Among the 88 adults, no significant association was found between tuberculous infection and BCG vaccination (OR 0.11, 95% CI 0.01 to 1.03).

### Multivariable analysis

Multivariable analysis was performed for the 168 children. In the fully adjusted model, BCG vaccination showed a significant

**Figure 1** Screening results for cases stratified by closest exposure to the index case.



protective effect for infection (OR 0.25, 95% CI 0.09 to 0.69). Similarly, being taught by the index case was an independent risk factor for acquiring tuberculous infection (OR 18.91, 95% CI 4.43 to 80.79, table 2).

**BCG vaccine effectiveness**

Using the adjusted OR for BCG vaccinated children acquiring TB infection, we calculated a corrected risk reduction<sup>14</sup> of 0.34 (95% CI 0.26 to 0.42). Using the formula  $VE=1-RR$ , this translates into a vaccine effectiveness of 0.66 or 66%, implying that 21 of the 32 infections could have been avoided if all children had been BCG vaccinated.

**Microbiological investigations**

DNA fingerprinting using the 15 loci-based Mycobacterium Interspersed Repetitive Units Variable Number Tandem Repeats (MIRU-VNTR) typing scheme<sup>15</sup> showed that the *M tuberculosis* strain (22 233 24 326 14 323, LAM lineage) of the index case was indistinguishable from the strains of two of the adults found to have sputum smear-positive TB. Sputum for culture of *M tuberculosis* was not available from any of the children.

**DISCUSSION**

We report extensive transmission of *M tuberculosis* among very young children with a prolonged exposure to an adult with sputum smear-positive TB. Furthermore, BCG seems to confer

a protective effect in children against *M tuberculosis* infection as assessed by positive IGRA in this cohort.

The UK national BCG immunisation policy was changed in 2005 from universal vaccination of school age children to an approach targeting high-risk infants. This policy change is supported by the International Union against Tuberculosis and Lung Disease consensus statement recommending this change in low-incidence areas,<sup>4 16</sup> and the change in TB epidemiology from a disease largely affecting the general population to that concentrated in particular high-risk groups. In addition, studies had indicated that the school programme was no longer a cost-effective public health measure<sup>17 18</sup> and the decline in TB incidence in the UK provided further support for the policy change.<sup>19</sup> Since 1998 the incidence of TB has increased in the UK, although this increase has been predominantly in high-risk groups.

Individual primary care trusts (PCTs) are responsible for the decision to implement universal or targeted BCG vaccination using recommended national criteria. Because of the high overall TB incidence, the diverse population and the large movement within London, more than half of the 26 PCTs in the city have now changed to a universal infant vaccination policy, including some areas with incidence of TB of <40/100 000. Most of the children in our outbreak cohort lived in the PCTs of Westminster and Kensington and Chelsea, both with a TB incidence of <40/100 000. These two PCTs introduced universal BCG vaccination

**Figure 2** Overview of the individuals screened in the outbreak broken down by BCG vaccination status and development of latent or active tuberculosis infection. ATB, active TB infection; BCG+, BCG vaccinated; BCG-, not BCG vaccinated; BCG NK, BCG vaccination status unknown; IGRA, interferon  $\gamma$  release assay; LTBI, latent TB infection; Neg, negative IGRA; no test, individual not screened for TB; TB, tuberculosis.

Total number of individuals screened											
N=256											
(index case not included)											
CHILDREN						ADULTS					
N=168						N=88					
BCG +		BCG -		BCG NK		BCG +		BCG -		BCG NK	
N=53		N=73		N=42		N=32		N=21		N=35	
LTBI	ATB	LTBI	ATB	LTBI	ATB	LTBI	ATB	LTBI	ATB	LTBI	ATB
N=6	N=1	N=19	N=7	N=5	N=1	N=1	N=1	N=5	N=0	N=6	N=2
Neg	No test	Neg	No test	Neg	No test	Neg	No test	Neg	No test	Neg	No test
N=46	N=0	N=47	N=0	N=21	N=15	N=30	N=0	N=16	N=0	N=17	N=10

**Table 1** Number of nursery contacts screened and outcome of the screening

Number screened	Contact with index case	Active TB disease	Latent TB infection	Attack rate (%)
24 (adults)	Teachers	2	7	37.5
7 (adults)	Guest teachers	0	0	0
57 (adults)	Parents and carers	1	5	10.5
86 (children)	Attended main nursery	7	28	40.7
30 (children)	Attended summer camp	0	0	0
52 (children)	Toddlers attended 1 h per week	2	2	9.4
256		12	42	21.1

of infants in 2005 and 2004, respectively, but the coverage is unknown and thought to be low.

Our results are unique in that they measure BCG effectiveness in a UK population in which universal infant vaccination is recommended. This is usually not the case in high-income countries where BCG is instead offered to risk groups. The latter skews the data as the vaccinated population has a higher risk of being exposed to TB compared with the unvaccinated population, leading to an apparent lack of protective effect of vaccination. As the children in this cohort are young, they have not been selected for vaccination following a negative tuberculin skin test result as was previously done with the school age BCG vaccination programme. This would have resulted in an apparent protective effect.

The affluent population affected in this outbreak is not generally perceived as being at appreciable risk of TB. The high international mobility of the group, however, potentially increases the risk of exposure to TB and the probability of being lost to follow-up in vaccination programmes. The majority also seek private healthcare with less close ties to the public health programmes.

It is widely accepted that BCG vaccination reduces the risk of severe forms of TB in infants.<sup>8–20</sup> The evidence for the effect of the BCG vaccine on the risk of tuberculous infection is more limited.<sup>7–12</sup> Only 42% of the children in this study were BCG vaccinated. This low coverage could be due to the children recently having moved to the area or because universal BCG vaccination for newborns was not actively promoted when these children were born.

Our results suggest that 21 of the 32 paediatric cases of TB infection in this study could have been prevented by BCG

vaccination. This should, however, be interpreted with caution. Our current knowledge of IGRA tests does not allow distinction between true latent TB infection and lasting immunological responses after exposure to *M. tuberculosis* infection.<sup>21</sup> Emerging evidence suggests that an IGRA test may not always correctly predict progression to active TB, but appears to be a more accurate indicator of the presence of latent TB infection than the tuberculin skin test.<sup>22–25</sup> However, IGRA testing provides at least the same or possibly higher sensitivity for detecting those who will progress to active TB compared with the tuberculin skin test.<sup>22–24</sup> Due to the young age of the children in this cohort, it seems unlikely that exposure prior to this outbreak is sufficient to explain the high probability of a positive IGRA. Nonetheless, data on IGRA in young children are scarce and should be interpreted carefully.<sup>21</sup> Only longitudinal follow-up studies will allow us to distinguish the lasting immunological response from latent infection.

The vaccine effectiveness of 66% found in our study is higher than the 38% reduction in RR found in another UK study<sup>9</sup> and the 24% reduction found in a larger and robust study by Soysal *et al.*<sup>12</sup> Overlapping CIs between the studies would suggest that the differences may not be significant. One of the reasons for this difference could be that the other studies investigated latent tuberculous infection in older children who could have acquired their infection prior to the period under investigation in the children. However, the children in the Turkish study<sup>12</sup> were also offered BCG vaccination at 2–3 months of age, similar to the children in our study.

One limitation of the study is the lack of information on BCG vaccination status from a part of the study population due to difficulties in coordinating the different private physicians who took care of some of the children. As mentioned above, it was not possible to perform tuberculin skin tests on the children. This might have been done at the same time as the IGRA test to be able to compare the results, as it has been shown that false negative IGRA results do occur.<sup>23–24</sup> However, it has been shown that IGRA results are not associated with previous BCG vaccination.<sup>10</sup> It should also be noted that the data are from an outbreak investigation and that the findings therefore are not necessarily generalisable to all situations. Furthermore, the study design used in this study can only identify an association between BCG vaccination and reduced risk of infection; only a randomised controlled trial could prove its protective efficacy as such.

**Table 2** Association between infection with *Mycobacterium tuberculosis* and risk factors for the 168 children in the outbreak population

		Not infected (%)	Infected (%)		Not infected (%)	Univariate OR (95% CI)	Multivariable OR (95% CI)	p Value (multivariable analysis)
			Latent	Active				
BCG vaccinated	Yes (n=53)	46 (87)	6 (11)	1 (2)	0	0.28 (0.11 to 0.70)	0.25 (0.09 to 0.69)	0.008
	No (n=73)	47 (64)	19 (26)	7 (10)	0	*	*	*
	NK (n=42)	21 (50)	5 (12)	1 (2)	15 (36)			
Age group	0–2 years (n=77)	58 (75)	9 (12)	4 (5)	6 (8)	*	*	*
	3–4 years (n=77)	49 (64)	20 (26)	5 (6)	3 (4)	2.28 (1.05 to 4.92)	0.36 (0.11 to 1.21)	0.098
	5–9 years (n=4)	3 (75)	1 (25)	0	0	1.49 (0.14 to 15.47)	0.89 (0.03 to 23.98)	0.946
	NK (n=10)	4 (40)	0	0	6 (60)			
Sex	Male (n=91)	62 (68)	15 (17)	3 (3)	11 (12)	*	*	*
	Female (n=77)	52 (68)	15 (19)	6 (8)	4 (5)	1.39 (0.67 to 2.89)	1.85 (0.71 to 4.78)	0.207
Index contact	Yes (n=86)	49 (57)	28 (33)	7 (8)	2 (2)	11.61 (3.87 to 34.83)	18.91 (4.43 to 80.79)	<0.001
	No (n=82)	65 (79)	2 (2.5)	2 (2.5)	13 (16)	*	*	*

Univariable ORs relate the odds of being an infected contact (as defined by IGRA positivity) for each risk factor. IGRA results are available for 153/168 children. The multivariate ORs are adjusted for all variables shown in the table and include the 123 children for which information was available for all the variables.

\*Referent.

NK, not known.



## CONCLUSION

We have used IGRA positivity as a measure for *M tuberculosis* infection and found a protective effect of BCG vaccination. These findings highlight the need to review the evidence for the effectiveness and cost effectiveness of BCG immunisation, in particular with regard to the current TB incidence cut-off level required for universal BCG vaccination in the UK. Owing to the high mobility across the boroughs of the city, we also recommend careful monitoring of TB incidence, BCG vaccination uptake and transfers across PCT boundaries within London among school children. Further research into better markers of latent tuberculous infection and longitudinal follow-up of exposed individuals is needed to find ways to distinguish individuals latently infected with live *M tuberculosis* from those who have persistent anti-mycobacterial immune responses without an increased risk of ever progressing to TB.

**Acknowledgements** The authors would like to thank all those who took part in the outbreak investigation, in particular Sheena Basnayake, Lesley Ruta, Marie O'Donoghue, Maria Mercer, the TB and paediatric teams at St Mary's and Chelsea and Westminster hospitals and the rest of the outbreak control team. The authors also thank Professor Paul Fine and Dr Doris Radun for reviewing and commenting on the manuscript.

**Competing interests** None.

**Ethics approval** This study was carried out during an outbreak investigation. The Health Protection Agency has Patient Information Advisory Group approval to hold and analyse communicable disease data for public health purposes under Section 60 of the Health and Social Care Act 2001.

**Contributors** JYC, VM and BW collected the data during the outbreak. EA and SW assessed, diagnosed and treated the children during the outbreak. JE and IA designed the analysis protocol. JE, IA and JYC analysed the data. JE and IA wrote the paper. JE, IA, JYC, VM, BW, EA and SW interpreted the data. JE, IA, JYC, VM, BW, EA and SW critically reviewed all material. JE and IA are guarantors.

**Provenance and peer review** Not commissioned; externally peer reviewed.

## REFERENCES

1. **Health Protection Agency Centre for Infections.** Tuberculosis in the UK: Annual report on tuberculosis surveillance in the UK 2008. London: Health Protection Agency, 2008.
2. **Abubakar I, Laundy MT, French CE, et al.** Epidemiology and treatment outcome of childhood tuberculosis in England and Wales: 1999–2006. *Arch Dis Child* 2008;**93**:1017–21.
3. **Department of Health.** Operational note to profession changes to the BCG vaccination programme in England, 2005. Department of Health, England. [http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH\\_4118134](http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_4118134).
4. **Anon.** Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease. *Tuberc Lung Dis* 1994;**75**:179–80.
5. **National Collaborating Centre for Chronic Conditions.** Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: Royal College of Physicians, 2006.
6. **Department of Health.** Immunisation against infectious disease—Tuberculosis. In: Ramsay ME, Salisbury D, Noakes K, eds. *Immunisation against infectious disease - 'The Green Book'*, 2006. Department of Health, England. [http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH\\_079917](http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_079917).
7. **Colditz GA, Berkey CS, Mosteller F, et al.** The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. *Pediatrics* 1995;**96**:29–35.
8. **Rodrigues LC, Diwan VK, Wheeler JG.** Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. *Int J Epidemiol* 1993;**22**:1154–8.
9. **Eisenhut M, Paranjothy S, Abubakar I, et al.** BCG vaccination reduces risk of infection with *Mycobacterium tuberculosis* as detected by gamma interferon release assay. *Vaccine* 2009;**27**:6116–20.
10. **Ewer K, Deeks J, Alvarez L, et al.** Comparison of T-cell-based assay with tuberculin skin test for diagnosis of *Mycobacterium tuberculosis* infection in a school tuberculosis outbreak. *Lancet* 2003;**361**:1168–73.
11. **Pulickal AS, Fernandez GV.** Comparison of the prevalence of tuberculosis infection in BCG vaccinated versus nonvaccinated school age children. *Indian Pediatr* 2007;**44**:344–7.
12. **Soysal A, Millington KA, Bakir M, et al.** Effect of BCG vaccination on risk of *Mycobacterium tuberculosis* infection in children with household tuberculosis contact: a prospective community-based study. *Lancet* 2005;**366**:1443–51.
13. **Veen J.** Microepidemics of tuberculosis: the stone-in-the-pond principle. *Tuberc Lung Dis* 1992;**73**:73–6.
14. **Zhang J, Yu KF.** What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. *JAMA* 1998;**280**:1690–1.
15. **Gibson A, Brown T, Baker L, et al.** Can 15-locus mycobacterial interspersed repetitive unit-variable-number tandem repeat analysis provide insight into the evolution of *Mycobacterium tuberculosis*? *Appl Environ Microbiol* 2005;**71**:8207–13.
16. **Joint Committee on Vaccines and Immunisation (JCVI).** Minutes of the JCVI BCG Subgroup, Thursday 7 April 2005.
17. **Springett VH, Sutherland I.** BCG vaccination of schoolchildren in England and Wales. *Thorax* 1990;**45**:83–8.
18. **Sutherland I, Springett VH.** The effects of the scheme for BCG vaccination of schoolchildren in England and Wales and the consequences of discontinuing the scheme at various dates. *J Epidemiol Community Health* 1989;**43**:15–24.
19. **Joint Committee on Vaccines and Immunisation.** Minutes of the JCVI BCG Subgroup, Tuesday 18 January 2005.
20. **Trunz BB, Fine P, Dye C.** Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. *Lancet* 2006;**367**:1173–80.
21. **Mack U, Migliori GB, Sester M, et al.** LTBI: latent tuberculosis infection or lasting immune responses to *M. tuberculosis*? A TBNET consensus statement. *Eur Respir J* 2009;**33**:956–73.
22. **Diel R, Loddenkemper R, Meywald-Walter K, et al.** Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with *Mycobacterium tuberculosis*. *Am J Respir Crit Care Med* 2008;**177**:1164–70.
23. **Kik SV, Franken WP, Mensen M, et al.** Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. *Eur Respir J* 2010;**35**:1346–53.
24. **Bakir M, Millington KA, Soysal A, et al.** Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. *Ann Intern Med* 2008;**149**:777–87.